Verve Therapeutics Inc [VERV] stock is trading at $4.59, up 1.77%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VERV shares have gain 50.49% over the last week, with a monthly amount drifted -22.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verve Therapeutics Inc [NASDAQ: VERV] stock has seen the most recent analyst activity on April 15, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight. Previously, H.C. Wainwright started tracking the stock with Buy rating on April 08, 2024, and set its price target to $15. On April 13, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $29 on the stock. Cantor Fitzgerald started tracking the stock assigning a Neutral rating and suggested a price target of $21 on February 01, 2023. Goldman initiated its recommendation with a Sell and recommended $13 as its price target on December 15, 2022. Credit Suisse started tracking with a Neutral rating for this stock on October 06, 2022, and assigned it a price target of $48. In a note dated August 25, 2022, Stifel upgraded an Buy rating on this stock and boosted its target price from $32 to $56.
Verve Therapeutics Inc [VERV] stock has fluctuated between $2.86 and $9.31 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Verve Therapeutics Inc [NASDAQ: VERV] shares were valued at $4.59 at the most recent close of the market. An investor can expect a potential return of 215.9% based on the average VERV price forecast.
Analyzing the VERV fundamentals
Verve Therapeutics Inc [NASDAQ:VERV] reported sales of 32.33M for the trailing twelve months, which represents a growth of 154.28%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -7.07%, Pretax Profit Margin comes in at -6.14%, and Net Profit Margin reading is -6.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.37 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.40 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.81, and for the 2nd resistance point, it is at 5.03.
Ratios To Look Out For
For context, Verve Therapeutics Inc’s Current Ratio is 12.65. Further, the Quick Ratio stands at 12.65, while the Cash Ratio is 4.02. Considering the valuation of this stock, the price to sales ratio is 12.61, the price to book ratio is 0.83.
Transactions by insiders
Recent insider trading involved Kathiresan Sekar, Chief Executive Officer, that happened on Apr 02 ’25 when 9822.0 shares were sold. Chief Administrative Officer, Nickerson Joan completed a deal on Apr 02 ’25 to sell 2777.0 shares. Meanwhile, Ashe Andrew D. sold 2681.0 shares on Apr 02 ’25.
